普拉克索对脑梗死后帕金森病的临床疗效及安全性分析.docx

? ? 普拉克索对脑梗死后帕金森病的临床疗效及安全性分析 ? ? 于莹　张娴 [摘要] 目的 观察普拉克索对脑梗死后帕金森病的临床治疗效果及不良反应。 方法 将2016年2月～2018年6月期间我院治疗的86例脑梗死后帕金森患者随机分为对照组和观察组，各43例，两组患者均予改善循环、抗凝等基础治疗，对照组在基础治疗上予左旋多巴治疗，观察组患者在基础治疗上加用普拉克索治疗，两组治疗均为8周，比较两组患者临床疗效、治疗前后UPDRSⅡ、Ⅲ评分结果、血清C-反应蛋白（CRP）、白细胞介素-6（IL-6）等炎性因子水平及用药期间不良反应等。 结果 观察组患者临床总有效率明显高于对照组，差异均有统计学意义（P0.05）;对照组患者用药期间不良反应发生率（11.63%）与观察组（13.95%）相比，差异无统计学意义。 结论 普拉克索治疗脑梗死后帕金森患者疗效显著，可降低患者血清炎症水平，提高患者日常生活能力及运动能力，安全性高，适合临床推广。 [关键词] 普拉克索;帕金森;脑梗死;安全性 [] R743.3;R742.5? ? ? ? ? [] B? ? ? ? ? [] 1673-9701（2019）11-0126-03 Clinical efficacy and safety of pramipexole in patients with Parkinsons disease after cerebral infarction YU Ying1? ?ZHANG Xian2 1.Department of Pharmacy， Jiamusi Central Hospital， Jiamusi? ?154000， China; 2.Department of Pharmacy， Chengdu First Peoples Hospital， Chengdu? ?610000， China [Abstract] Objective To observe the clinical effect and adverse reactions of pramipexole in patients with Parkinsons disease after cerebral infarction. Methods 86 patients with Parkinsons disease after cerebral infarction treated in our hospital from February 2016 to June 2018 were randomly divided into control group and observation group， with 43 cases in each group. Both groups were treated with basic therapy such as improvement of circulation and anticoagulation. The control group was treated with levodopa on the basis of basic treatment. The patients in the observation group were treated with pramipexole on the basis of basic treatment. Both groups were treated for 8 weeks. The clinical efficacy of the two groups， UPDRSⅡ， Ⅲ scores before and after treatment， serum C-reactive protein（CRP）， interleukin-6 （IL-6） and other inflammatory factors and adverse reactions during the treatment were compared. Results The total clinical effective rate of the observation group was significantly higher than that of the control group（P0.05）. The incidence of adverse reactions during the treatment was not significantly different between the control group（11.63%） and the observation group（1